Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -47% Improvement Relative Risk Hospitalization time -60% Ramakrishnan et al. Cannabidiol for COVID-19 Prophylaxis Is prophylaxis with cannabidiol beneficial for COVID-19? Retrospective 6,291 patients in the USA (January - December 2020) Higher hospitalization with cannabidiol (p=0.0001) Ramakrishnan et al., The J. Clinical Psychiatry, doi:10.4088/JCP.21m14332 Favors cannabidiol Favors control
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes
Ramakrishnan et al., The Journal of Clinical Psychiatry, doi:10.4088/JCP.21m14332
Ramakrishnan et al., Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes, The Journal of Clinical Psychiatry, doi:10.4088/JCP.21m14332
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 6,291 COVID-19 patients in the USA, showing higher mean hospital admissions and higher maximum length of hospitalization with cannabis use disorder.
Results for cannabis use disorder patients may differ from other use of cannabis.
risk of hospitalization, 47.2% higher, RR 1.47, p < 0.001, treatment 20, control 6,271, mean number of admissions.
hospitalization time, 60.1% higher, relative time 1.60, p = 0.004, treatment 20, control 6,271, maximum length of hospitalization.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ramakrishnan et al., 29 Aug 2022, retrospective, USA, peer-reviewed, 4 authors, study period January 2020 - December 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes
BS Divya Ramakrishnan, MS Soundari Sureshanand, MS Brian Pittman, MBBS Rajiv Radhakrishnan
The Journal of Clinical Psychiatry, doi:10.4088/jcp.21m14332
Early Career Psychiatrists CME Background Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results. To obtain credit, read the article, correctly answer the questions in the Posttest, and complete the Evaluation. CME Objective After studying this article, you should be able to: • Understand which SUDs and other psychiatric patient subgroups may be more susceptible to severe COVID-19 infections and outcomes and better direct needed medical attention to these patients. Accreditation Statement The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
For reprints or permissions, contact ♦ © 2022 Copyright Physicians Postgraduate Press, Inc. It is illegal to post this copyrighted PDF on any website. Posttest To obtain credit, go to to take this Posttest and complete the Evaluation.
Allen, Shahawy, Rogers, Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020, J Public Health (Oxf)
Baillargeon, Polychronopoulou, Kuo, The impact of substance use disorder on COVID-19 outcomes, Psychiatr Serv
Egede, Dawson, Walker, Relationship between mental health diagnoses and COVID-19 test positivity, hospitalization, and mortality in Southeast Wisconsin, Psychol Med, doi:10.1017/S0033291721002312
Fond, Nemani, Etchecopar-Etchart, Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and metaanalysis, JAMA Psychiatry, doi:10.1001/jamapsychiatry.2021.2274
Fond, Pauly, Leone, Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: a national cohort study, Schizophr Bull
Jeon, Kwon, Park, Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study, Br J Psychiatry, doi:10.1192/bjp.2020.251
Lee, Yang, Moon, Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study, Lancet Psychiatry, doi:10.1016/S2215-0366(20)30421-1
Li, Li, Fortunati, Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.23282
Nemani, Li, Olfson, Association of psychiatric disorders with mortality among patients with COVID-19, JAMA Psychiatry, doi:10.1001/jamapsychiatry.2020.4442
P U B M E D C R O S S R E F ; King, Jt, Yoon, Rentsch, None, doi:10.1080/10826084.2020.1791184
P U B M E D C R O S S R E F, None, doi:10.1002/wps.20806
P U B M E D C R O S S R E F, None, doi:10.1038/s41380-020-00880-7
P U B M E D C R O S S R E F, None, doi:10.1093/schbul/sbaa158
P U B M E D C R O S S R E F, None, doi:10.1176/
Schimmel, Manini, Opioid use disorder and COVID-19: biological plausibility for worsened outcomes, Subst Use Misuse
Vai, Mazza, Colli, Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and metaanalysis, Lancet Psychiatry, doi:10.1016/S2215-0366(21)00232-7
Wang, Kaelber, Xu, COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States, Mol Psychiatry
Wang, Xu, Volkow, Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States, World Psychiatry
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop